DRMAW
Dermata Therapeutics, Inc. NASDAQ$0.02
Mkt Cap $10,769
52w Low $0.01
38.8% of range
52w High $0.02
50d MA $0.02
200d MA $0.02
P/E (TTM)
0.0x
EV/EBITDA
967.4x
P/B
0.0x
Debt/Equity
0.0x
ROE
—
P/FCF
-0.0x
RSI (14)
—
ATR (14)
—
Beta
0.50
50d MA
$0.02
200d MA
$0.02
Avg Volume
7.7K
About
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -1.54 | -0.35 | +77.3% | 0.02 | -21.4% | -22.3% | -22.7% | -16.8% | -28.6% | -25.0% | — |
| Nov 14, 2025 | AMC | -1.59 | -1.65 | -3.7% | 0.02 | +27.5% | +9.4% | +0.6% | +6.4% | +8.2% | +10.5% | — |
| Aug 13, 2025 | AMC | -2.90 | -1.66 | +42.9% | 0.02 | -5.8% | +15.2% | -7.9% | -6.8% | +13.6% | +16.2% | — |
| May 14, 2025 | AMC | -4.50 | -0.45 | +90.1% | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.54 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -1.73 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2022 | AMC | — | -0.13 | — | — | — | — | — | — | — | — | — |
Data updated apr 28, 2026 6:53am
· Source: massive.com